--- title: "Neoadjuvant Ovarian Cancer DESTINY-Ovarian01 | Sutter Health" description: "A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)" url: "https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Neoadjuvant Ovarian Cancer DESTINY-Ovarian01 # Neoadjuvant Ovarian Cancer DESTINY-Ovarian01 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819007). #### Locations - Sunnyvale - Mountain View #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13) ![M Dwight Chen, M.D.](https://dyn.mktgcdn.com/p/J48cE196XGUbsJt8Ata2Dizc28a9ojbAW3JGOeEFIZI/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) M Dwight Chen, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/m-dwight-chen-md-1049681047) ## Sub-Investigators [Gillian L Hsieh, M.D.](https://www.sutterhealth.org/research/investigators/gillian-l-hsieh-md-1049681038) , [Eva Y Louie, ANP, N.P., M.S., MPH, OCN](https://www.sutterhealth.org/research/investigators/eva-y-louie-anp-np-ms-mph-ocn-2060811542) ## Email us to enroll - [Email Sunnyvale](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Neoadjuvant%20Ovarian%20Cancer%20DESTINY-Ovarian01%20in%20Sunnyvale&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Mountain View](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Neoadjuvant%20Ovarian%20Cancer%20DESTINY-Ovarian01%20in%20Mountain%20View&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB](https://www.sutterhealth.org/research/clinical-trials/adjuvant-advance-ovarian-cancer-framework-01-j5e-mc-jzxb-2066913418) FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Ovarian Cancer NRG-GY036](https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362) A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy **Status:** Open to Enrollment - Clinical trial ### [Advanced Ovarian Cancer Catalina-2](https://www.sutterhealth.org/research/clinical-trials/advanced-ovarian-cancer-catalina-2-2023017569) Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002) **Status:** Open to Enrollment - Clinical trial ### [Advanced Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer GOG-3115](https://www.sutterhealth.org/research/clinical-trials/advanced-serous-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-gog-3115-2041490051) A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRĪ±-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer **Status:** Open to Enrollment - Clinical trial ### [Ovarian Cancer M25-709 FLORENZA](https://www.sutterhealth.org/research/clinical-trials/ovarian-cancer-m25-709-florenza-2040407243) A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Neoadjuvant Ovarian Cancer DESTINY-Ovarian01"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496#medicalwebpage","name":"Neoadjuvant Ovarian Cancer DESTINY-Ovarian01","description":"A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496","inLanguage":"en-US","dateModified":"2026-06-08","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496#breadcrumblist"},"mentions":[{"@type":"Person","name":"M Dwight Chen, M.D.","url":"https://www.sutterhealth.org/research/investigators/m-dwight-chen-md-1049681047","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496#medicaltrial","name":"Neoadjuvant Ovarian Cancer DESTINY-Ovarian01","alternateName":"A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496","description":"A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)","identifier":"NCT06819007","code":{"@type":"MedicalCode","codeValue":"NCT06819007","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06819007","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Ovarian Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sunnyvale"},{"@type":"AdministrativeArea","name":"Mountain View"}]} ```